Genus's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 3.2% per year. EPS is expected to decline by 0.6% per annum. Return on equity is forecast to be 10.4% in 3 years.
Key information
-2.7%
Earnings growth rate
-0.62%
EPS growth rate
Biotechs earnings growth
25.2%
Revenue growth rate
3.2%
Future return on equity
10.36%
Analyst coverage
Good
Last updated
11 May 2026
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
OTCPK:GENS.F - Analysts future estimates and past financials data (GBP Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
6/30/2028
705
65
72
106
9
6/30/2027
690
58
65
98
12
6/30/2026
677
126
57
78
12
12/31/2025
672
48
46
64
N/A
9/30/2025
672
33
47
66
N/A
6/30/2025
673
19
49
67
N/A
3/31/2025
672
8
40
58
N/A
12/31/2024
672
-4
31
49
N/A
9/30/2024
670
2
18
40
N/A
6/30/2024
669
8
5
30
N/A
3/31/2024
671
21
8
37
N/A
12/31/2023
673
33
10
45
N/A
9/30/2023
681
33
13
48
N/A
6/30/2023
690
33
15
50
N/A
3/31/2023
676
34
-1
42
N/A
12/31/2022
662
34
-18
35
N/A
9/30/2022
628
38
-25
34
N/A
6/30/2022
593
41
-31
34
N/A
3/31/2022
582
39
-20
39
N/A
12/31/2021
570
37
-9
43
N/A
9/30/2021
572
42
13
55
N/A
6/30/2021
574
47
34
68
N/A
3/31/2021
570
45
42
70
N/A
12/31/2020
566
42
50
72
N/A
9/30/2020
559
39
40
66
N/A
6/30/2020
551
35
30
60
N/A
3/31/2020
536
37
25
55
N/A
12/31/2019
520
39
19
49
N/A
9/30/2019
504
23
N/A
41
N/A
6/30/2019
489
8
N/A
33
N/A
3/31/2019
480
1
N/A
35
N/A
12/31/2018
471
-7
N/A
37
N/A
9/30/2018
470
18
N/A
40
N/A
6/30/2018
470
43
N/A
43
N/A
3/31/2018
473
55
N/A
42
N/A
12/31/2017
476
67
N/A
41
N/A
9/30/2017
467
50
N/A
38
N/A
6/30/2017
459
33
N/A
35
N/A
3/31/2017
441
40
N/A
34
N/A
12/31/2016
422
47
N/A
33
N/A
9/30/2016
405
48
N/A
31
N/A
6/30/2016
388
49
N/A
30
N/A
3/31/2016
388
40
N/A
25
N/A
12/31/2015
388
31
N/A
21
N/A
9/30/2015
393
35
N/A
28
N/A
6/30/2015
399
40
N/A
35
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GENS.F's earnings are forecast to decline over the next 3 years (-2.7% per year).
Earnings vs Market: GENS.F's earnings are forecast to decline over the next 3 years (-2.7% per year).
High Growth Earnings: GENS.F's earnings are forecast to decline over the next 3 years.
Revenue vs Market: GENS.F's revenue (3.2% per year) is forecast to grow slower than the US market (11.7% per year).
High Growth Revenue: GENS.F's revenue (3.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GENS.F's Return on Equity is forecast to be low in 3 years time (10.4%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/17 14:28
End of Day Share Price
2026/05/13 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genus plc is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.